Better Therapeutics (Nasdaq:BTTX) announced today that it appointed Diane Gomez-Thinnes as its new chief commercial officer (CCO).
Gomez-Thinnes’ appointment became effective yesterday, Oct. 26, 2022. She joins the San Francisco-based company, which develops prescription digital therapeutics (PDTs). They use a novel form of cognitive behavioral therapy (CBT) to address the root causes of cardiometabolic diseases, including diabetes. The company last month submitted its BT-001 digital therapeutic for type 2 diabetes to the FDA for de novo classification.
“We could not be more pleased to welcome such an accomplished and well-respected executive to the Better Therapeutics team,” said Frank Karbe, CEO of Better Therapeutics. “Diane has an extensive track record of building and leading highly successful commercial businesses, in areas including first-of-kind medical devices. As we look to launch the first prescription digital therapeutic for type 2 diabetes, if the FDA authorizes BT-001 for marketing, it will be Diane who helps us write the playbook for what a successful launch in this new and promising space looks like.”
About Better Therapeutics’ new CCO
Gomez-Thinnes holds more than two decades of experience in the healthcare industry. Over the course of her career, she led the commercialization and launch of products in the medical device, prescription medicine and consumer health sectors. She worked for companies including Johnson & Johnson and Galderma, the latter of which she led as president of U.S. operations.
At Galderma, Gomez-Thinnes delivered double-digit growth in her leadership role. She launched more than 20 products, including drug delivery technology, aesthetic products and a refreshed consumer product line.
Before Galderma, Gomez-Thinnes spent 17 years at J&J. She served as worldwide president for Mentor, the breast aesthetics arm of J&J.
She said in the release that Better Therapeutics attracted her because of its quest to tackle “huge health problems with such an innovative approach.” Gomez-Thinnes labeled it clinically promising and said it could potentially improve quality of life “at a scale that simply was not possible before.”
“Having an opportunity to set the standard for what prescription digital therapeutics may accomplish was something that I could not pass up,” said Gomez-Thinnes. “With prescription digital therapeutics rooted in CBT, we have a chance to change how we treat epidemic, chronic conditions like type 2 diabetes, fatty liver disease, heart disease and more by giving individuals control over their own health. And we can do this in a way that reaches more patients, especially those who experience disparities in access to health treatments and services.”